SuanFarma-Header SuanFarma-Header


Find Approved Drugs for Genetic Disease in Clinical Development in CANADA


All Data

Filters Filter
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type


            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Plasminogen

            Therapeutic Area: Genetic Disease Product Name: Ryplazim

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kedrion

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement June 23, 2021


            This acquisition would include the Ryplazim® (plasminogen, human-tvmh) (“Ryplazim®”) business operated through its subsidiaries, Prometic Bioproduction Inc., the Company’s plasma-derived therapeutics manufacturing facility (“PBP”), and Prometic Biotherapeutics Inc.